13 completed. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
Follow Genital Warts: new trials by email Literature Review of Genital Warts trials Research Report on Genital Warts
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts Quadrivalent HPV vaccine, Hepatitis B vaccine - Genital Warts | Phase 3 | Completed | University of Pretoria | 52 | 2018-07-01 | 2026-01-23 |
| Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) V503 - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1212 | 2017-09-20 | 2019-11-21 |
| Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) 9vHPV Vaccine - Genital Warts, Anal Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2520 | 2012-10-29 | 2018-11-27 |
| A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) V503, Placebo to V503 - Cervical Cancers, Vulvar Cancers | Phase 3 | Completed | Merck Sharp & Dohme LLC | 924 | 2010-02-24 | 2018-11-27 |
| Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts 2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream - Genital Warts | Phase 3 | Completed | Graceway Pharmaceuticals, LLC | 511 | 2008-08-01 | 2011-07-20 |
| Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Imiquimod, 3.75% imiquimod cream, placebo cream - Genital Warts | Phase 3 | Completed | Graceway Pharmaceuticals, LLC | 470 | 2008-05-01 | 2011-05-24 |
| Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Comparator: GARDASIL, Experimental: V503 - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 14840 | 2007-09-24 | 2018-11-27 |
| A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine HPV (Human Papillomavirus) Vaccine - Cervical Cancer, Genital Warts | Phase 3 | Completed | Simon Dobson | 830 | 2007-07-01 | 2015-04-10 |
| Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine - Cervical Cancer, Genital Warts | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3055 | 2002-12-01 | 2015-01-13 |
| Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years - Cervical Cancer, Genital Warts | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3882 | 2002-06-28 | 2017-03-22 |
| Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine, Matching Placebo - Cervical Cancer, Genital Warts | Phase 3 | Completed | Merck Sharp & Dohme LLC | 12167 | 2002-06-14 | 2025-08-01 |
| Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years, Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years - Cervical Cancer, Genital Warts | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1877 | 2001-12-28 | 2017-03-22 |
| Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) V501, Comparator: Placebo, Human Papillomavirus (HPV) 16 Monovalent - Cervical Cancer, Genital Warts | Phase 3 | Completed | Merck Sharp & Dohme LLC | 5759 | 2001-12-01 | 2015-09-25 |
Condylomata Acuminata (13) · Uterine Cervical Neoplasms (9) · Vaginal Neoplasms (3) · Vulvar Neoplasms (3) · Papillomavirus Infections (2) · Anus Neoplasms (1)
Communicable Diseases (13) · DNA Virus Infections (13) · Disease Attributes (13) · Genital Diseases (13) · Infections (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Sexually Transmitted Diseases (13) · Sexually Transmitted Diseases, Viral (13) · Skin Diseases (13) · Skin Diseases, Infectious (13) · Skin Diseases, Viral (13) · Skin and Connective Tissue Diseases (13) · Tumor Virus Infections (13) · Urogenital Diseases (13)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (7) · Vaccines, Synthetic (4) · Duration of Therapy (2) · Papillomavirus Vaccines (2) · Hepatitis B Vaccines (1) · Imiquimod (1) · Vaccines (1)
Merck Sharp & Dohme LLC (9) · Graceway Pharmaceuticals, LLC (2) · Simon Dobson (1) · University of Pretoria (1)
United States (2) · Austria (1) · Belgium (1) · Canada (1) · Finland (1) · Germany (1) · Italy (1) · South Africa (1) · Spain (1)
Jason Wu, MD (2) · David Scheifele, MD (1) · Greta G Dreyer, MMed(O&G)PhD (1) · Joanne Langley, MD (1) · Marc Dionne, MD (1) · Meena Dawar, MD (1) · Scott Halperin, MD (1) · Shelly McNeil, MD (1) · Simon Dobson, MD (1) · Tobias Kollman, MD (1)
PMID 19236277, PMID 19236279, PMID 19935017, PMID 27422279, PMID 30982556, PMID 32184277, PMID 41166720, PMID 20949623, PMID 21471141, PMID 22454089, PMID 23066159, PMID 23299013, PMID 29074187, PMID 29211620, PMID 29995724, PMID 18164106, PMID 19116707, PMID 19453788, PMID 19505910, PMID 20647284, PMID 21248158, PMID 21300618, PMID 21307649, PMID 21491420, PMID 22469863, PMID 23632723, PMID 24055350, PMID 25278227, PMID 25693011, PMID 25749310, PMID 25912208, PMID 26366475, PMID 26411885, PMID 28789851, PMID 28886907, PMID 29029053, PMID 29269325, PMID 29767739, PMID 32247041, PMID 33326342, PMID 33676783, PMID 35149535, PMID 35525430, PMID 41276263